Clinical
Trials
Harnessing The Power Of Science For Patient Benefit
By embracing challenging experiments and asking difficult questions, we act with urgency to discover and develop medicines that will have a meaningful impact on patients with cancer. Designed with clinically relevant endpoints and predefined benchmarks for success, our trials are designed to promote efficient decisions to accelerate a program when promising data emerges.
Our Clinical Trials
Asset/Study
Zipalertinib (CLN-081/TAS6417)
The REZILIENT 1 Trial, a Phase 1/2a, Open-label, multicenter, first-in-human trial in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations.
Design
Evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy
Status
Recruiting
Study ID
NCT04036682Asset/Study
CLN-049A Phase 1, open-label, multicenter, first-in-human study of CLN-049 in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Design
A study investigating the safety, tolerability, PK, PD, and preliminary efficacy.
Status
Recruiting
Study ID
Asset/Study
CLN-619A Phase 1, open-label, multicenter study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Design
A study investigating the safety, efficacy, PK, and PD activity.Status
Recruiting
Study ID
Asset/Study
CLN-418 (HBM7008)
A Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CLN-418 (HBM7008), and to determine the maximum tolerated dose and/or recommended Phase 2 study dose in patients with advanced solid tumors.
Design
A Phase 1 monotherapy dose escalation/expansion study.Status
Recruiting
Study ID